MedTrace Logo

RESIPI for Reducing Perioperative Major Adverse Cardiac Events

NCT03208023 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2022-11-17

No results posted yet for this study

Summary

This study aims to evaluate the effect of a novel hemodynamic management and monitoring strategy for reducing cardiac bio marker elevations and major adverse cardiac events.

Conditions

  • Inotropy
  • Fluid Management
  • Cardiac Event
  • Perioperative Cardiac Risk
  • Vascular Resistance
  • Hemodynamic Monitoring
  • Hemodynamic Management
  • Fluid Responsiveness

Interventions

PROCEDURE

RESIPI Management Strategy

a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical, Inc).

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Cheetah Medical Inc.

    collaborator INDUSTRY

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Matthew D McEvoy, M.D. · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-09
Primary Completion
2018-11-01
Completion
2018-12-03

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03208023 on ClinicalTrials.gov